We observed few changes among treatment cohorts in tumor properties, with the tumor maintaining an HLA class I (high), class II (low), poliovirus receptor (PVR; high), and PD-L1 (low) profile, although the PVR inhibitory receptor was significantly downregulated on tumor cells in the triple therapy cohort (Supplementary Fig. S4C). The gene discussed is CD274; the disease is neoplasm.